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Background: Diarrhea-predominant irritable bowel syndrome (IBS-d) significantly diminishes the health-related
quality of life (HRQOL) of patients. Psychological and social impacts are common with many IBS-d patients reporting
comorbid depression, anxiety, decreased intimacy, and lost working days. The Irritable Bowel Syndrome Quality
of Life (IBS-QOL) questionnaire is a 34-item instrument developed and validated for measurement of HRQOL in
non-subtyped IBS patients. The current paper assesses this previously-validated instrument employing data collected
from 754 patients who participated in a randomized clinical trial of a novel treatment, eluxadoline, for IBS-d.
Methods: Psychometric methods common to HRQOL research were employed to evaluate the IBS-QOL. Many
of the historical analyses of the IBS-QOL validations were used. Other techniques that extended the original
methods were applied where more appropriate for the current dataset. In IBS-d patients, we analyzed the items
and substructure of the IBS-QOL via item reduction, factor structure, internal consistency, reproducibility, construct
validity, and ability to detect change.
Results: This study supports the IBS-QOL as a psychometrically valid measure. Factor analyses suggested that
IBS-specific QOL as measured by the IBS-QOL is a unidimensional construct. Construct validity was further
buttressed by significant correlations between IBS-QOL total scores and related measures of IBS-d severity including
the historically-relevant Irritable Bowel Syndrome Adequate Relief (IBS-AR) item and the FDA’s Clinical Responder
definition. The IBS-QOL also showed a significant ability to detect change as evidenced by analysis of treatment
effects. A minority of the items, unrelated to the IBS-d, performed less well by the standards set by the original
authors.
Conclusions: We established that the IBS-QOL total score is a psychometrically valid measure of HRQOL in IBS-d
patients enrolled in this study. Our analyses suggest that the IBS-QOL items demonstrate very good construct
validity and ability to detect changes due to treatment effects. Furthermore, our analyses suggest that the IBS-QOL
items measure a univariate construct and we believe further modeling of the IBS-QOL from an item response theory
(IRT) approach under both non-treatment and treatment conditions would greatly further our understanding as
item-based methods could be used to develop a short form.
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Irritable bowel syndrome (IBS) affects an estimated
10-15% of people in western cultures [1]. It is character-
ized by recurrent abdominal pain and diarrhea [2] and
can negatively impact health-related quality of life
(HRQOL). IBS subtypes are defined by Rome III and in-
clude: diarrhea (IBS-d), constipation (IBS-c), or mixed
constipation and diarrhea (IBS-m) [3]. Safe and effective
pharmacologic treatments for IBS are limited, with
current treatment options including antispasmodics, an-
tidepressants, antidiarrheal agents, and alosetron [4]. Re-
cently, clinical outcome results from a large Phase 2
clinical trial in IBS-d patients of a novel mixed mu-
opioid (μ-OR) agonist, delta-opioid (δ-OR) antagonist,
eluxadoline, were reported [5]. Additionally, HRQOL in-
struments were included in the study as secondary out-
comes. By subjecting this larger data set to procedures
outlined by previous publications [6,7] we plan to con-
firm the original psychometric validation analyses of the
non-subtyped IBS-QOL. More specifically, we hope to
assess how the IBS-QOL performs in strictly IBS-d
patients.
Historical development and validation of the IBS-QOL
Patrick, et al., describe the steps utilized for item con-
struction to ensure content validity of the IBS-QOL
items [6,8] in which a combination of forty IBS-d, IBS-c,
and IBS-m patients were interviewed resulting in identi-
fication of 117 potential items to describe these patients’
IBS. Next, 30 additional patients underwent cognitive
debriefing interviews which led to the retention of 45
items from the pool. After review by HRQOL and gastro-
enterology experts from Europe 41 items were found to be
sufficiently content valid for use in the United States,
Britain, Germany, Italy, and France. This pilot question-
naire was then mailed to 169 patients who: a) met Rome
criteria for IBS, [9] b) were symptomatic at least 2 days/
week, and c) were aged 18 to 65; 156 patients responded:
60% IBS-m, 22%, IBS-c, and 19% IBS-d.
Drossman, et al., extended the validation of the IBS-
QOL by collecting questionnaires from 156 females with
a functional bowel disorder [7]. These patients had mod-
erate to severe symptoms ≥ 2 days/week over 3 months.
Patients were assessed the two weeks prior to start of
treatment and again after 12 weeks. For abdominal pain,
visual analog reports were averaged over the two-week
intervals from Week−2 to treatment start and Weeks
11-12.
Drossman, et al., [10] further investigated the IBS-
QOL’s ability to detect treatment changes. After utilizing
pain and treatment satisfaction as anchors for interpret-
ing IBS-QOL total scores from a sample of mostly fe-
male IBS patients, the authors concluded that a 14-point
improvement in IBS-QOL scoring was clinically mea-ningful. In the current paper, we will examine the IBS-
QOL total score improvement keeping the Drossman,
et al., improvement of 14-points as a historical reference
point.
Psychometric evaluations utilized in these studies
included:
 Item reduction.
 Factor structure analysis employing principal
components analysis (PCA) with orthogonal
rotation using the varimax method.
 Internal consistency reliability assessed by
Cronbach’s Coefficient α.
 Reproducibility via comparing the overall IBS-QOL
score at Baseline and one week later using the
Intraclass Correlation Coefficient (ICC).
 Construct validity determined by correlational
analyses for convergence and divergence of
IBS-QOL scores with other clinical measures.
 Ability to detect change assessed by statistical
comparison of change scores in the IBS-QOL
in response to treatment.
 Comparisons among a priori determined responder
groups to aid in the interpretation of the IBS-QOL
changes in scores due to treatment effects.
Additional file 1 contains the final instrument of 34
items consisting of 8 subscale domains determined by
the original work. Previous research has demonstrated
that the IBS-QOL is internally consistent, highly reliable,
has convergent and divergent validity, and acceptable re-
sponsiveness to treatment effects.
Methods
The goal of the current paper is to replicate the original
IBS-QOL validation by using similar methodologies
as previous efforts but with attention specifically to the
IBS-d patient population [6,7]. Psychometric and statis-
tical techniques were applied to 753 patients aged
18-65 years who completed the IBS-QOL at their Base-
line visit. Between May 2010 and April 2011, 292 study
centers obtained informed consent enrolled 807 patients
into the study, with women representing approximately
70% of patients. A list of study investigators appears in
Additional file 2. All patients all met the Rome III cri-
teria for IBS-d [2], were compliant with their daily diary
during the week prior to randomization, received at least
one dose of double-blind study medication, and had at
least one post-randomization diary entry. They also had
to meet minimal requirements for presence of abdom-
inal pain and stool consistency ratings. Patients were
required to complete the electronic diary on 6 of the 7
required days during the week prior to randomization
AND on 11 of the 14 required days during the 2 weeks
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in completing the screening diary on a daily basis on
6 of the 7 required days during the week prior to
randomization AND on 11 of the 14 required days dur-
ing the 2 weeks prior to randomization, had an average
of daily worst abdominal pain ratings of 3.0 or greater
over the previous week, had a weekly mean Bristol Stool
Score of 5.5 or greater over the previous week, and who
had not used any rescue medication in the preceding
2 weeks were eligible for participation and immediate
randomization into the double blind treatment phase.
Conduct of the trial was overseen by Institutional
Review Boards and complied with the Declaration of
Helsinki. Patients in the trial completed the IBS-QOL,
as well as other outcome measures, over 3 months while
receiving either placebo or an active dose of eluxadoline
(5, 25, 100, or 200 mg) twice daily [5]. HRQOL instru-
ments included the IBS-QOL, Adequate Relief (IBS-AR),
and IBS-Symptom Severity Score (IBS-SSS) [11]. These
were collected periodically and Dove, et al., detail further
the design and conduct of the trial. For the trial data,
many of the psychometric assessments were applied to
baseline data so that possible treatment effects did not
confound the results. Other assessments were made in
the presence of treatment effects and these are described
below.
Assessments of pretreatment measurements
The potential for item reduction was assessed by apply-
ing the item-inclusion criteria from the original valid-
ation study [6]. Criteria were applied to the IBS-QOL
instrument to see if differences exist between the current
large IBS-d sample and the smaller, original, non-
subtyped IBS validation sample. The criteria assessed
included:
 50% of patients responded “not at all” and therefore
could not improve on the item
 5% or more missing data
 an item-to-total correlation of <0.4 indicating
that the item may be measuring a different latent
construct
 pairwise correlations between individual items
that exceeded 0.7 indicating redundancies in
measurement.
The original factor structure of the IBS-QOL and
possible alternative subscale structures were assessed.
Several Confirmatory Factor Analysis (CFA) models
were fit via maximum likelihood. Diagrams outlining the
different conceptual models are included in Additional
file 3: Figure S1. The first model corresponds to the ori-
ginal PCA and assumes orthogonal factors adequately
measure independent subdomains of IBS-related QOL.The likelihood ratio χ2, Akaike Information Criterion
(AIC), and Schwartz’s Bayesian Information Criterion
(BIC) were used as indicators of model fit; smaller values
are generally considered better. A second, hierarchical
CFA was fit which imposed the original structure, but
also assumes that the subscales themselves form a gener-
alized factor, [12] presumably, the latent construct of
HRQOL in IBS. Hierarchical factor analyses employ a
two-step approach; the items are grouped into factors
and then the factors are submitted to factor analysis.
The third and fourth models fit were confirmatory
bi-factor models [13]. The bi-factor approach was
employed to refine the strictly hierarchical HRQOL con-
ceptualizations as this method allows for a structure
whereby subscales may explain variance not necessarily
associated with the general QOL factor. Items were or-
ganized into 8 subscales and a general factor with each
item having hypothesized relationships to one subscale
and the general factor [14]. For example, Item 12 is hy-
pothesized to load onto the Sexual subscale and also the
general construct of HRQOL in IBS. The two bi-factor
models included: one with orthogonal factors, i.e., in
which the model does not allow factors to correlate with
one another; and an oblique one in which correlations
between factors are allowed. A single factor model in
which all items load onto a single factor was also fit for
reference to the other CFA models. Such a model im-
poses a structure in which all items load onto one gen-
eral factor representing HRQOL in IBS.
Because CFA models involve fitting complex multi-
variate data, model fit is evaluated by inspecting several
fit indices [15]. Numerous fit indices have been sug-
gested, but minimally, a CFA model should be evaluated
for fit based on a combination of different indices [16]
as each assess different aspects of the model. Indices fit
included:
 Goodness of Fit Index (GFI). An analogue to the R2
in regression where higher values are considered
better. GFI values of 1.0 indicate perfect fit in that
all observed variance is accounted for by the
proposed model [17].
 Comparative Fit Index (CFI). This index assesses the
amount of variance the model fits above and beyond
a null model, i.e., one with no structure [17]. The
CFI has a range of 0 to 1 and generally should be
above 0.9 for good fit.
 Root Mean Square Error of Approximation
(RMSEA). This index assesses the fit of the model
according to a noncentral χ2 distribution that is
determined by the degrees of freedom of the model
[17]. Values range from 0 to infinity with smaller
values being better; less than 0.05 indicates excellent
fit, greater than 0.1 indicates poor fit.
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good fit is indicated by values between−0.1 and 0.1.
To investigate possible misspecification of any CFA
models, an Exploratory Factor Analysis (EFA) of the
items was conducted to evaluate what structure would
be suggested by the current data sample. EFA imposes
no a priori structure to the data [12] and is similar to
the approach taken by Patrick, et al. [6].
So-called internal consistency reliability was assessed
by computing Coefficient α for the 34-item IBS-QOL
total score as well as the Coefficient α-value for all (n-1)
combinations, i.e., the so-called α-if-item-deleted, to
gauge influence of single items. Values of α above 0.7 in-
dicate a good level of consistency with values above 0.9
being considered excellent. Extremely high values can
call into question whether scale items could be elimi-
nated because of redundancy.
Assessments including postbaseline measurements
Consistency of the IBS-QOL total score over time is
usually evaluated by correlating responses over repeated
measurements. All administrations of the IBS-QOL post
Baseline were in the presence of treatment, thus, a
traditional ICC would be biased by treatment in the
current case. To account for treatment effects and time
trajectories on the IBS-QOL total score, reliability was
assessed by first estimating variances via a linear model
and utilizing the resultant conditional variances to estab-
lish reliability. Such an approach has been developed
and described in two papers by Laenen, et al. [18,19].
Their reliability measures, RΛ and RT, utilize estimated
variances from a linear model to calculate reliability over
the set of repeated measurements, conditional on the
covariates. Thus, in lieu of calculating an ICC, reprodu-
cibility was assessed via fitting longitudinal models to
the repeated administrations of the IBS-QOL accounting
for treatment effect over the treatment period. Details of
the approaches are given in Additional file 4.
Construct validity of the IBS-QOL total score was
assessed by evaluating it in relation to other clinical out-
comes. For the IBS-SSS and EQ-5D, Pearson correlations
at Baseline and Week 12 were calculated. Since the scale
of the IBS-SSS is opposite to that of the IBS-QOL, a
negative correlation between it and the IBS-QOL total
score indicates convergence. A positive correlation with
the EQ-5D indicates IBS-QOL converging with general
HRQOL.
Further, change from Baseline to Week 12 in IBS-
QOL total scores were correlated with similar changes
from Baseline for IBS-SSS, EQ-5D, and average worst
abdominal pain (WAP) [7]. The change score for the
WAP variable was calculated as the average of WAP rat-
ings for Weeks 11and12 compared to the average for thetwo weeks prior to dosing and the average of WAP for
Week 12 compared to the average in the week prior to
dosing.
Additionally, correlations between the IBS-QOL total
score with the IBS-AR and FDA Clinical Responder
status were calculated. The IBS-AR is a historically-used
global measure of change used for assessing relief in IBS.
A single item, “Over the past week have you had ad-
equate relief of your IBS symptoms?” is administered to
the patient and they respond either “Yes” or “No.” Des-
pite its established value as an endpoint measure for
clinical trials dissatisfaction by regulatory agencies with
the IBS-AR has led to the desire to develop quantifiable
symptom based patient-reported outcome (PRO) mea-
sures for IBS [20]. Pending the development of a final
IBS PRO, the FDA issued a guidance document in 2012
for drug development in IBS in which they formulated
responder analysis definitions based on diary collection
of pain and stool consistency ratings. One of the FDA
Clinical Responder definitions from the Guidance, uti-
lized by Dove, et al., is also used in the current paper as
an additional criterion for assessing the validity of the
IBS-QOL total score [5]. The definition is based on a
percentage of days a patient has a simultaneous im-
provement in both pain and stool consistency on the
same day—the so-called daily responder definition [21].
Since these outcomes are measured on a dichotomous
scale two different biserial correlation approaches were
calculated to account for non-continuous variables
[22,23]. See Additional file 5 for a full description of the
approaches.
The IBS-QOL was previously assessed for responsive-
ness [7] using Cohen’s d statistic [24]. In that analysis,
effect sizes for the change in scores from pre-treatment
to post-treatment were computed similarly to standar-
dize mean differences by putting changes in scores into
standard deviation units. The d statistic originally
employed a standard deviation value that was either
based on the Baseline pooled data or on the control
group only. Both of these methods inherently assume
homogeneity of variance, either across time points or
across treatment groups. To account for potential het-
erogeneity of variance across treatment groups and also
handle data dependencies due to repeated patient mea-
surements an additional assessment was calculated by
estimating a longitudinal model for the change in IBS-
QOL total score between Baseline and Week 12 admin-
istrations. To visually assess the IBS-QOL total score,
the cumulative proportion of patients meeting a
certain change from Baseline to Week 12 was also
plotted by treatment group and the proportion of
patients meeting certain thresholds of improvement
for Placebo and Eluxadoline 100 mg treatment groups
were compared.
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3.0, [25] R-package ltm, [26] and SAS® software version
9.3 [27].
Trial registration: ClinicalTrials.gov identifier
NCT01130272.
Results
Of the 754 patients included for analysis, 526 were fe-
male and 646 were Caucasian. The mean (standard devi-
ation) age was 44.8 (11.93) with Baseline IBS-QOL total
scores averaging 53.2 (21.09).
Assessments of pretreatment measurements
For Baseline data, Table 1 displays items that warrant
further investigation as they did not meet the original
qualitative criteria for inclusion. Of note, while several
items displayed relatively high inter-item correlations,
two items, 32 and 33, had a majority of patients respond
with the, “not at all” category. Item 29, notably, had the
opposite problem where many patients responded with
the highest category, “a great deal.” While not restrictive
in the sense that patients cannot improve on this item,
such a skewed distribution could cause problems with
other items when scoring or modeling is conducted.
Such results are also indicative that either a reduced re-
sponse set is adequate. For example, in our dataset
46.4% patients reported “not at all” for Item 33 (“My
bowel problems are affecting my closest relationships”),
so simply providing a “yes” versus “no” response set to
this item may be adequate for IBS-d patients. Alterna-
tively, the items may not be helpful in measuring the
latent construct of interest in IBS-d patients.
Table 2 displays the various fit statistics for the CFA
models. Moderately good CFA fits were observed withTable 1 Potentially problematic items according to criteria in
Item
6. I feel like I’m losing control of my life because of my bowel problems.
7. I feel my life is less enjoyable because of my bowel problems.
9. I feel depressed about my bowel problems.
10. I feel isolated form others because of my bowel problems.
12. Because of my bowel problems, sexual activity is difficult for me.
20. My bowel problems reduce my sexual desire.
29. It is important to be near a toilet because of my bowel problems.
30. My life revolves around my bowel problems.
32. I fear I won’t be able to have a bowel movement.
33. My bowel problems are affecting my closest relationshipsthe exception of the single factor model. In general,
models should demonstrate GFI values similar to R2 in
regression and trending above 0.85 or so and CFI—an
index that compares the fitted model to a null base
model—should be above 0.9. For both these indices, lar-
ger values are better. Also, findings from the RMSEA,
where smaller values are better, suggest moderately-
good fits since results fall between 0.05 and 0.1. Add-
itionally, Table 2 presents both the average residual size
and the percentage of residual values that fall outside of
the (−0.1, 0.1) interval.
As with the CFA models, the EFA model was fitted
for Baseline values of the IBS-QOL. The goal of the
EFA was to elucidate any moderate fit of the CFAs
to the data. The factor pattern loadings for the EFA
solutions are compared with the subscales in Table 3;
three of eight original subscales correspond one-to-
one with the substructures of the data, i.e., “Body
Image”, “Food Avoidance”, and “Sexual”; the other
five factors only approximately fit the original sub-
structure. The most notable departure is with Factor
1, which is a mixture of items from the “Social Reac-
tion”, “Relationship”, and sporadic items from other
subscales.
Coefficient α analysis of the IBS-QOL total score
demonstrated a high level of reliability between items
of the IBS-QOL [α = 0.963, 95% confidence interval
(0.959, 0.966)]. Additional file 6: Table S1 lists the
full α item analysis. All but Item 32 (“I fear I won’t
be able to have a bowel Movement”) had item-to-
total correlations above 0.5. The α-value with Item
32 included is still extraordinarily high without delet-
ing this item, however. In fact, deleting any one item
does not reduce the Coefficient α-value by more thanPatrick, et al. [6]
Reason(s) why item is problematic
• High item-to-item correlation: r6,7 = 0.732
• High item-to-item correlation: r6,10 = 0.702
• High item-to-item correlation: r7,6 = 0.732
• High item-to-item correlation: r9,10 = 0.707
• High item-to-item correlation: r10,6 = 0.732
• High item-to-item correlation: r10,9 = 0.707
• High item-to-item correlation: r12,20 = 0.741
• High item-to-item correlation: r20,12 = 0.741
• High item-to-item correlation: r29,30 = 0.708
• Potential ceiling effect: 38.9% of patients reporting, “a great deal”
• High item-to-item correlation: r30,29 = 0.708
• Floor effect: 72.8% of patients reporting “not at all”
• Low item-total correlation: r32,Total = 0.292
• Potential floor effect: 46.4% of patients reporting “not at all”
Table 2 Comparison of confirmatory factor model fit statistics
Statistic Subscales only Hierarchical Orthogonal Bi-factor Oblique Bi-factor Single factor
χ2 2441.1 2616.9 2254.9 1923.3 3755.9
(df) (499) (519) (496) (468) (527)
AIC 2633.1 2768.9 2452.9 2193.3 3891.9
BIC 3075.7 3119.4 2909.3 2815.7 4205.5
GFI 0.8232 0.8088 0.8346 0.8616 0.7378
CFI 0.877 0.8671 0.8889 0.9073 0.7955
RMSEA 0.072 0.074 0.069 0.066 0.091
(95% CI) (0.070, 0.075) (0.071, 0.077) (0.066, 0.072) (0.063, 0.069) (0.089, 0.094)
Average Residual 0.0588 0.062 0.053 0.0448 0.0632
% of Residuals ≥ 0.1 or≤ −0.1 18.7% 21.2% 16.0% 10.5% 20.0%
Note: χ2 = Likelihood ratio χ2; df = χ2 degrees of freedom; AIC = Akaike’s Information Criterion (smaller is better); BIC = Schwartz’s Bayesian Information Criterion
(smaller is better); GFI = Goodness-of-Fit Index (Acceptable fit > 0.9); CFI = Bentler’s Comparative Fit Index (Good fit > 0.9); RMSEA = root-mean-square error of
approximation (Very good fit <0.05;Moderate fit between 0.05 and 0.1); CI = confidence interval.
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was r = 0.642, indicating a high consistency between
item responses.
Assessments including postbaseline measurements
The longitudinal model showed that both RΛ and RT
had very good reliability for the data with RΛ = 0.89 and
RT = 0.76. By comparison, Patrick, et al., reported an
ICC between administrations of 0.86. This indicates the
stability of IBS-QOL total scores when treatment and
time effects are taken into account as well as consistency
with previous assessment.
Correlations between IBS-QOL total score and change
scores for IBS-SSS, EQ-5D, 14-day WAP, the 7-day
WAP, IBS-AR, and the FDA Clinical Responder values
are presented in Table 4. All correlations show statistical
significance. Several show moderate to strong linear re-
lationships (r ≥ 0.40) between other variables and the
IBS-QOL total score. Further, all correlations were in
the correct direction given the scales of measurement of
the variables.Table 3 Comparison between original subscale structure and
EFA Mod
Original subscale Factor 1 Factor 2
(37.8) (3.20)
Dysphoria 13, 16 1, 6, 7, 9, 10




Social reaction 14, 17, 34
Sexual
Relationship 8, 24, 33
Note: Eigenvalues for the extracted factors are in parentheses and higher values rep
given factor.Table 5 displays the analyses of treatment effects de-
tected by the IBS-QOL. Similar patterns of discrimin-
ation are observed whether calculations were conducted
on the observed changes from baseline or estimated via
longitudinal modeling. Additionally, effect sizes based on
the pooled standard deviation between groups evaluated
for the standard deviation of the Placebo group at Base-
line revealed the same pattern with effect size estimates
being of similar magnitude. The attenuation of effect
sizes relative to Placebo was expected as the standard
deviation of the Placebo group at Baseline is expected to
be larger. Further, the larger disparity observed in the
longitudinal model between pooled- and placebo-based
effect size estimates was also expected as the estimate
for the pooled standard deviation in the longitudinal
model takes repeated measurement information into
account.
Figure 1 displays the cumulative proportion of patients
meeting a certain change from Baseline by treatment
group. Consistent with previous results [5] the higher
dose groups demonstrated better improvements in IBS-data-suggested structure
el with Varimax Rotation (Eigenvalues)
Factor 3 Factor 4 Factor 5 Factor 6
(2.48) (1.76) (1.46) (1.24)
30
3, 27, 29, 31 22 19





resent higher amounts of the variance observed in the data captured by a
Table 4 Partial correlations between IBS-QOL total score and other clinical measures—controlling for dose level
Variable Time point N Correlation type Correlation value p-Value
IBS-SSS Week 12 427 Pearson −0.604 <0.0001
Change from Baseline 383 Pearson −0.629 <0.0001
EQ-5D Week 12 694 Pearson 0.581 <0.0001
Change from Baseline 690 Pearson 0.404 <0.0001
Pain/14-Day Week 12 550 Pearson −0.392 <0.0001
Change from Baseline 549 Pearson −0.350 <0.0001
Pain/7-Day Week 12 536 Pearson −0.397 <0.0001
Change from Baseline 535 Pearson −0.357 <0.0001








Note: Point biserial and biserial correlation coefficients are evaluated via constructing a t-test.
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crimination between Placebo and Eluxadoline 100 mg
treatment groups. For this pairwise comparison,
higher proportions of Eluxadoline-treated patients
were observed for a wide range of improvement
levels. Over 80% of placebo patients and over 90% of
patients treated with Eluxadoline 100 mg had the
same score or higher at Week 12 as compared to
Baseline. Furthermore, this approximate 10% differ-
ence between these two treatment groups persisted
or increased if the criterion was raised all the way
up to 30 points of improvement. Interestingly, the





IBS-QOL total score, Observed Data(a)
5 mg 66 19.7
25 mg 135 18.7
100 mg 130 25.2
200 mg 107 25.0
Placebo 125 17.7
IBS-QOL total score, Longitudinal Model(b)
5 mg 105 19.3
25 mg 167 18.4
100 mg 163 24.5
200 mg 160 23.3
Placebo 159 17.3
Note: (a) Effect size estimates based on observed standard deviations (sPooled, sPlaceb
mixed-effects model for IBS-QOL total score with fixed effects of treatment, time, tr
effects for intercept and time σ^ Pooled ; σ^ Placeboð Þ.met by 48% of the placebo patients and over 65% of
eluxadoline 100 mg patients and the maximum group
difference was observed for a 22 point improvement
in which over 25% of placebo patients and over 47%
of eluxadoline 100 mg patients responded, respect-
ively, for a group difference of 21.5%.
Discussion
The goal of the current paper was to replicate and ex-
pand on the original psychometric assessment of the
IBS-QOL when applied to an IBS-d-specific patient set.
Our results indicate that male and female IBS-d patients








3 2.02 0.64 189 0.522 0.09 0.09
5 1.04 0.43 258 0.664 0.05 0.05
5 7.54 3.10 253 0.002 0.39 0.33
6 7.35 2.68 230 0.008 0.35 0.32
0
3 2.00 1.09 262 0.279 0.13 0.09
6 1.13 0.67 324 0.507 0.07 0.05
3 7.20 4.20 320 <.001 0.47 0.31
3 6.00 3.64 317 <.001 0.41 0.26
3
o) (b) Effect size estimates based on estimated standard deviations from a
eatment by time interaction, and Baseline IBS-QOL total score and random
Figure 1 Cumulative proportions of patients meeting a certain change from Baseline to Week 12 in IBS-QOL total scores plotted by
treatment group.
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criteria for diarrhea as defined by the BSS share com-
monalities with a general population of non-subtyped
IBS patients, but that the originally-proposed subscale
structure doesn’t apply as well as one might anticipate
to our patient set. The deviations observed from the ori-
ginal assessment could be attributed to the fact that we
evaluated IBS-d patients or due to the much larger sam-
ple size employed here. Without such large-scale data
on other IBS subtypes, it is difficult to discern the cause
of the departures from the original analyses, but in the
case that one or both differences are influencing the
current results, it is still clear that the IBS-QOL per-
forms well for IBS-d patients.
The item reduction criteria applied to the 34-item ver-
sion of the IBS-QOL resulted in many items having high
bivariate correlations, as defined as r ≥ 0.7. A possible
factor influencing the high correlations between items
could be due to priming or order effects, i.e., responses
on subsequent items being influenced by earlier-
answered items. As the IBS-QOL is a static instrument
with only one item order presented to patients, however,
testing whether priming influences responses by patients
to single items is not possible.
Alternatively, high correlations between items could
suggest that the items are measuring a single latent trait.Table 6 Percentages of patients meeting different levels of IB







30 19.1%Items 6 (“I feel like I’m losing control of my life because
of my bowel problems”), 7 (“I feel my life is less
enjoyable because of my bowel problems”), 9 (“I feel
depressed about my bowel problems”), and 10 (“I feel
isolated from others because of my bowel problems”) all
showed a fairly high level of correlation with one an-
other. The α-value for the overall sum scale of the IBS-
QOL is also very high, suggesting redundancies across
these items.
Similarly, Items 12 (“Because of my bowel problems,
sexual activity is difficult for me”) and 20 (“My bowel
problems reduce my sexual desire”) exhibited a high cor-
relation with one another (r = 0.741) as expected. Both
items make up the Sexual subscale and while the lan-
guage of the two items respectively imply physical and
psychological aspects of sexual activity, patient responses
tended to suggest that one does not occur without the
other.
There were several other pairs of items that exhibited
high inter-item correlation values (cf., Table 1). Our re-
sults suggest that a possible future research path for the
IBS-QOL is to explore whether a shortened version of
the IBS-QOL targeted toward IBS-d could be con-
structed from the current items while maintaining its
measurement properties and still being relevant to IBS-d
patients. If items have redundancy, then one couldS-QOL total score improvement
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slightly different versions of the IBS-QOL. Alternatively,
specific cognitive debriefing may also help isolate
whether any of these items are truly redundant or if
items all closely measure HRQOL in IBS-d and simply
represent very closely related aspects of IBS-d-related
QOL.
Conversely, in IBS-d patients, a departure from the
original validation analyses was not surprising either. For
example, 72.8% IBS-d patients answered “Not at all” to
Item 32 (“I fear I won’t be able to have a bowel move-
ment”) at Baseline. This result fits, conceptually, with
how patients should answer items that are not geared to-
ward their IBS subset. This item, therefore, could be taken
out of a targeted IBS-d instrument or, perhaps, could sim-
ply be included with a binary, “yes” versus “no”, response
instead of the 5-point graded response set.
While some of the results suggested that certain items
in the IBS-QOL may be candidates to remove if a
reduced-item version were to be sought for IBS-d pa-
tients, other results support that the full set of items is
relevant and psychometrically sound, consistent with
conclusions of previous validation studies of the IBS-
QOL. This result is not surprising given the extremely
high value of Cronbach’s Coefficient α (α = 0.963). This
is consistent with the interpretation of the bi-factor and
EFA models because the common interpretation of
Coefficient α analyses is that the items are internally
consistent and therefore represent a unidimensional
latent construct.
This conclusion is reinforced by a high observed aver-
age item-to-total correlation of 0.642. However, one of
the limitations here is that modern applications of α
analysis stretch interpretation of the statistic beyond its
original intent [28]. Coefficient α was intended to substi-
tute alternate forms reliability—in which two equivalent
forms of the instrument were to be administered and
the results correlated with one another. As most instru-
ment developers do not have the resources to develop
two instruments together, Coefficient α was devised as a
means of assessing agreement between an instrument
and a theoretical one of same length, comprised of items
randomly drawn from all possible content valid items.
The coefficient, therefore, is laden with assumptions and
also is, ostensibly, a lower bound for the theoretical true
internal consistency of a measure. Many have criticized
the use of α for this and other reasons [29-31]. Fur-
ther, while an α assessment assumes sum of item
responses, the IBS-QOL standardizes responses to a
0-100 scale, so without further study, it is not clear
how the scoring algorithm relates back to a simple
sum score. Structural equation modeling techniques,
e.g., extensions of the CFA models, actually offer the
best alternatives to α and other individual indices asthey are better equipped to handle multivariate item
data [32,33]. However, any positive or negative bias
around the α-value of 0.96 would likely still yield ac-
ceptable levels of consistency.
In terms of how the items structurally relate to one
another at the instrument level, the fact that the oblique
bi-factor model fits the data the best, and better than
the orthogonal bi-factor model, suggests that the original
factor structure is redundant to the total sum score be-
cause factors that are allowed to be correlated fit better
with the data than hypothetically independent subscales.
We do note, however, that more complex CFA models
tended to fit better by both standard fit indexes and
usual assessment of residuals and that, generally, in-
creasing model complexity provides better fit in most
statistical models. While the oblique bi-factor model
accounted for a marginal amount of variance (GFI =
0.8616), an acceptable improvement in variance above a
null model (CFI = 0.9073) was observed. The RMSEA
index imposes a penalty for higher complexity models,
thereby allowing us to infer whether the bi-factor models
fit better according to other indices based on their com-
plexity. The observed RMSEA value of 0.069, although
moderate in size, comparatively supports the oblique
bi-factor conceptualization of IBS-d, i.e., that the best of
all CFA models fit is on with an overall latent factor sup-
ported by the original substructure whilst allowing the
substructure factors to correlate with one another. The
model fit may have room for improvement as 10.5% of
residuals are outside of the preferred limits potentially
indicating that some items may not fit well within the
proposed structure.
The EFA model supports that there may be pairs or
subsets of items of the IBS-QOL that group together
more so than with others—an observation that is not
surprising given the observed inter-correlations between
items. Interestingly, though, the EFA fit did not produce
a factor structure in line with the original substructure,
suggesting that HRQOL may be qualitatively different
for IBS-d as compared to non-subtyped IBS patients as a
whole.
Despite the extraction of multiple factors from the
analysis, the EFA fit actually further strengthens the in-
terpretation that the IBS-QOL is unidimensional in IBS-
d patients. This is because the EFA model has a large
first eigenvalue (37.8) as compared to the second (3.8).
Eigenvalues of extracted factors measure the amount of
variance observed in the items making up that factor.
Here the first extracted factor accounts for 79.5% of the
total variance in the items. Further, a test of whether
the items suggest a structure in which there is at least
one common factor to all items was also significant
[χ2(561) = 16,080.2, p <0.0001] implying that any struc-
ture extracted after that first factor is residual
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first factor, but one factor would be adequate to inter-
pret the construct under study. This observation indi-
cates that imposing the original factor structure [6] is
helping model fit, implying that the original subscale
structure of the IBS-QOL seems to be beneficial in ac-
counting for information above and beyond the total
sum score. Furthermore, combined with the fit of the or-
thogonal bi-factor model results, one could conclude for
IBS-d patients that the IBS-QOL may be measuring a
unidimensional construct, both because of the need to
allow factors to correlate and that the original substruc-
ture seems only approximately correct.
The CFA and EFA modeling, taken together, suggest
that perhaps the best means of assessing the psychomet-
ric properties of the IBS-QOL would be to employ Item
Response Theory (IRT) methods [34]. IRT approaches
estimate a latent construct via a joint model of the
individual items. IRT models can also help determine if
individual items are performing as intended within the
IBS-QOL because relationships between items and the
latent trait under study are estimated, directly.
In terms of test-retest reliability, the current analyses
demonstrated good levels for the IBS-QOL total score in
this regard. Both RΛ and RT exceed the traditionally-
accepted reliability threshold of around 0.7 and were
comparable to the ICC calculated by the original valid-
ation study. Both reliability measures employed here are
similar to ICCs with slightly different interpretations. RΛ
is the multivariate reliability of the sequence of scores
while RT is the average reliability for the total score over
any arbitrary number of administrations. Both will tend
to increase for a consistent instrument with more ad-
ministrations because additional information is being
taken into account with each added administration.
Therefore, with 3 post-Baseline administrations of the
IBS-QOL, we have substantial evidence for good reliabil-
ity of the total score. Contrastingly, even with less infor-
mation, e.g., two administrations of the IBS-QOL, we
would expect that a reliability level would still be ap-
proximately 0.75 by our estimates.
The analysis of IBS-QOL total scores with regard to
responsiveness were consistent across effect size defini-
tions for different paired comparisons, with moderate
increases in effect sizes seen for higher doses of eluxado-
line versus placebo. Interestingly, the pattern of effect
size estimates suggest that the 100 mg dose of eluxado-
line had the largest impact, the same conclusion as was
reached by the analysis of clinical measures [5] as de-
fined in FDA’s 2012 IBS Guidance [21]. This conclusion
is bolstered by evaluating the cumulative proportions of
change from Baseline to Week 12 scores for the IBS-
QOL total score with better improvements seen at
higher dose levels, specifically 100 and 200 mg. Weespecially note that within a wide range of improvement
levels, the proportion of patients in the eluxadoline
100 mg group meeting given improvements was dramat-
ically higher than those patients receiving placebo. This
indicates that the observed treatment effect in the IBS-
QOL total score is consistent. Visually, this result is ap-
parent by the wide gap between the placebo and 100 mg
eluxadoline lines on Figure 1.
Of note, all treatment groups showed large increases
in IBS-QOL total scores at Week 12 as compared to
Baseline. Even the Placebo group showed an approxi-
mately 17-point increase in total score—higher than
the 14-point clinically-significant difference found by
Drossman, et al [10]. While further longitudinal study is
warranted, we believe that the improvement may be
due to natural cycling of disease or due to potential
Hawthorne effects, ie, improvements by patients as a re-
sult of simply being observed. We do, however, also note
that the treatment group differences approximate a dose
response that peaks at 100 mg and plateaus with
200 mg. This pattern mimics that of the other outcome
measures reported elsewhere [5].
Our analyses suggest that a reduced-form IBS-QOL
specific for IBS-d sufferers may improve measurement
of IBS-related QOL for these patients. However, further
research is necessary to determine which of the items
may be ideally suited for a reduced form. We suggest
that a better characterization of item-level properties of
the IBS-QOL via IRT methodology would be helpful in
determining an optimal item configuration.
Conclusions
Much of the original development and validation work
on the IBS-QOL items were replicated in the current
paper. However, some items do not appear perform
ideally for IBS-d patients, either individually or with one
another, and a reduced-item set for the IBS-QOL may
produce better overall measurement of the IBS-d condi-
tion. Despite some indications of improvements that
could be made, the current 34-item instrument does
work in IBS-d patients; it performs well on the classical
set of psychometric assessments and is demonstrated to
be: Approximately unidimensional as evidenced by the
high first eigenvalue extracted from the EFA model as
well as the high Coefficient α value observed among the
items; reliable as evidenced by the consistently high RΛ
and RT values; and correlated with other measures of
IBS-d symptoms and outcomes—both new, like the FDA
Clinical Responders, and old, i.e., IBS-AR. Combined
with good ability to detect change, evidenced by moder-
ately high effect sizes in changes from Baseline to Week
12 and good discrimination of the 100 mg dose versus
placebo over a wide range of improvement levels—cf.
Figure 1—we believe that the IBS-QOL total score is a
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patients.
There are indications that the individual items do con-
tain more information than what is expressed in a sum
or scaled total score. Thus, directly relating items to the
latent construct of IBS-d-specific QOL via IRT modeling
should be considered for future research on the IBS-
QOL to determine if there are untapped measurement
properties within the items. Taken together, the current
results suggest the IBS-QOL is a psychometrically sound
instrument for patients with diarrhea predominant IBS
and the total score is a good, unified measure of
HRQOL. Importantly, all of the results together suggest
that the IBS-QOL appears to detect the core concepts of
IBS-d as well as changes in the disease state. Further, the
relatively high observed correlations between the IBS-
QOL and other established efficacy measures reinforces
the conclusion that the IBS-QOL is not only a reliable,
but also a valid and sensitive measure of patients’ IBS-d
experiences.
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